Status
Conditions
Treatments
About
Evaluation of Tumor Bed Cavity Shaving as an Oncologically Safe Alternative to Frozen Section Analysis in Breast-Conserving Surgery and aim of study To assess the oncological safety and practicality of tumor bed cavity shaving also aims to evaluate its impact on operative time and overall cost.
Full description
Breast cancer remains the most common malignancy among women worldwide and represents a major health burden. Breast-conserving surgery (BCS) has become the standard of care for early-stage breast cancer, aiming to achieve complete tumor excision with histologically clear margins combined with adjuvant radiotherapy, offers equivalent survival rates to mastectomy in early-stage cases.
. Positive surgical margins are strongly associated with increased rates of local recurrence and frequently necessitate re-excision.
Traditionally, intraoperative frozen section analysis (FSA) has been used to assess margin status. However, this technique has several drawbacks, including:
Limited availability in many centers.
Requires high-experienced cytopathologists making it challenging in resource-limited places.
Adds substantial cost.
Time consuming (prolonged operative time).
tumor bed cavity shaving (TBCS) means additional thin layers of tissue approximately 5:10 mm in thickness are removed circumferentially from the cavity walls .
With many advantages:
feasible in centers lacking intraoperative pathological facilities.
Time saving (significantly reduces the overall operative time).
cost-effectiveness.
Technically simple (Easy to perform without the need for specialized equipment or advanced facilities).
it represents a suitable option in low- to medium-socioeconomic settings, where resources and advanced intraoperative support may be limited.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
-Contraindication of Breast-Conserving Surgery.
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Nagm elden Abu elnaga, Ph D; Mark Ezzat Gerges, Resident doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal